中文版English

Home | Add to Favorites | Contact Us

Home >> Department >> Innovation Platform >> Beijing Key Laboratory of Polymorphic Drugs

Beijing Key Laboratory of Polymorphic Drugs

 

Beijing Key Laboratory of Polymorphic Drugs, which is based on Center of Pharmaceutical Polymorphism of Institute of Materia Medica, is the earliest key laboratory specializing on the study of pharmaceutical polymorphism relying on the Pharmaceutical Science Key Discipline accredited previously by the Ministry of Education. The studies of polymorphism involve the areas of medicinal chemistry, pharmaceutics, pharmaceutical analytical chemistry, pharmacokinetics and dynamics. The laboratory successfully passed certification in May, 2012, and has solid theoretical and technical foundations and abundant experiences of polymorphic research, and plays a key role in related academic fields. Prof. Yang LU is the director of laboratory and Prof. Guanhua DU (Director of Chinese Pharmacological Society, Vice President of Institutes of Pharmaceutical Science, Chinese Academy of Medical Science) is the director of academic committee. The laboratory now has over 60 faculty members and graduates, with 7 full professors, 3 associate professors, 4 Ph.D. supervisors and 4 M.Sc. supervisors.
To create a first-class platform for research and development of pharmaceutical polymorphism, which has the capability of leading the development of techniques and improving the quality and standards of pharmaceutical polymorphism, and equalizing the domestic drugs with imports. To accomplish the polymorphic studies of Class I innovative drugs, generic drugs, and drug transformations of basic varieties. Provide professional services and technical supports of pharmaceutical polymorphism to Beijing and the rest of the country.
In recent five years, the laboratory participated in Mega-Projects for “11th Five-Year” and “12th Five-Year” Plans, National Program on Key Basic Research Project, and other national and provincial level grants and projects. Over 30 graduates were awarded master or PhD degrees, and over 300 research papers have been published, over 100 of which were published in SCI -indexed journals. The Laboratory has filed over 40 patents applications, 10 of which were licensed, and set 185 national standards with national reference material certificates. The Laboratory also established platforms of chemical techniques, analytical techniques, quality standards, mechanism, and biological evaluations of pharmaceutical polymorphs. The Laboratory has 8 Class1 polymorphic innovative drugs at different stages, two under phase II clinic trials, two under phase I clinic trials, one received trial permission, and three under preclinical development.
Beijing Key Laboratory of Polymorphic Drugs plays a key role in the aspects of investigating key techniques for the development of new and generic drugs, , setting pharmaceutical polymorphism standards, and delivering the drug quality control The Laboratory has now appropriately undertaken 70 percent of research and development tasks in the area of pharmaceutical polymorphism, while annually provides hundreds of technical services for over 300 institutes, academies, and pharmaceutical enterprises. As a third-party institution, the key laboratory has undertaken the tasks of testing and verifying polymorphic materials, providing technical supporting in judicial disputes, and compiling of polymorphic associated clauses in the national pharmacopeia. The establishment of Beijing Key Laboratory of Polymorphic Drugs may help high-techniques benefit Beijing and expand to the whole country, which will provide technical supports and services to the national pharmaceutical industry.